It was during the charting step that we began to realize our inability to answer our research question.
However, the indications for warfarin reversal were different (P = <0.001, chi-square test), despite our efforts to remove non-life-threatening cases during chart review of the FFP cohort.
The information to differentiate between these two groups was not available during chart review.
Additionally, during chart abstraction we encountered a very small amount (<5%) of missing data.
Only four omissions in the radiotherapy prescription were found during chart round.
This ensured that we had an adequate number of relevant resuscitation events to evaluate during chart review.
A median of five people were present during chart round each week (interquartile range 2 to 8).
Furthermore, some patient data remained unreported because it could not be found in physician notes during chart abstraction.
Included were women diagnosed with invasive breast cancer, identified using ICD-9 174 and confirmed during chart abstraction.
To ensure patient confidentiality, no patient identifiers were extracted during chart review and only unique study codes were entered into the database.
